Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) from a hold rating to a buy rating in a research report released on Monday, July 17th. The firm currently has $119.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
GWPH has been the topic of a number of other research reports. Maxim Group started coverage on shares of GW Pharmaceuticals PLC in a research note on Thursday, April 20th. They set a buy rating and a $135.00 target price on the stock. Cantor Fitzgerald reaffirmed a buy rating and set a $208.00 target price on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. TheStreet lowered shares of GW Pharmaceuticals PLC from a c- rating to a d+ rating in a research note on Wednesday, May 10th. BidaskClub raised shares of GW Pharmaceuticals PLC from a strong sell rating to a sell rating in a research note on Wednesday, June 14th. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Wednesday, June 21st. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $156.38.
GW Pharmaceuticals PLC (GWPH) opened at 117.21 on Monday. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88. The stock’s 50 day moving average is $104.85 and its 200 day moving average is $114.17. The firm’s market cap is $2.97 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.50) by $0.20. The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. GW Pharmaceuticals PLC’s revenue was down 23.0% on a year-over-year basis. During the same period last year, the business earned ($0.06) EPS. On average, analysts predict that GW Pharmaceuticals PLC will post ($5.10) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC (GWPH) Upgraded by Zacks Investment Research to Buy” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/07/30/gw-pharmaceuticals-plc-gwph-lifted-to-buy-at-zacks-investment-research-updated.html.
A number of large investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its stake in GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 264 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in GW Pharmaceuticals PLC during the second quarter valued at approximately $204,000. Blair William & Co. IL acquired a new stake in GW Pharmaceuticals PLC during the first quarter valued at approximately $207,000. Nwam LLC acquired a new stake in GW Pharmaceuticals PLC during the first quarter valued at approximately $208,000. Finally, Tudor Investment Corp Et Al acquired a new stake in GW Pharmaceuticals PLC during the fourth quarter valued at approximately $219,000. 75.63% of the stock is currently owned by institutional investors and hedge funds.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.
